Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

750
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Motor Unit Number and Size Estimation With Muscle Thickness and Strength in Healthy Young, Middle-Aged, and Older Adults.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2026
Same author

A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS.

Communications biology·2025
Same author

[Neuromuscular Ultrasound: Diagnosis and Evaluation in Neuromuscular Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2024
Same author

Neurophysiological and imaging biomarkers of lower motor neuron dysfunction in motor neuron diseases/amyotrophic lateral sclerosis: IFCN handbook chapter.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2024
Same author

Diagnostic utility of Gold Coast criteria for amyotrophic lateral sclerosis in Asia.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2024
Same author

[Charcot-Marie-Tooth disease Patient Registry in Japan].

Rinsho shinkeigaku = Clinical neurology·2023
Same journal

[Neuropathological Autopsies in Japan: Current Scenario and Challenges].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Telemedicine and Digital Technologies in Neurological Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Disaster Countermeasures for Intractable Neurological Disease].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Supporting Health Care Transition for Patients with Childhood-Onset Chronic Conditions: Within Intractable Disease Care in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Multidisciplinary Collaboration between Hospitals and Clinics at the University Hospital and the Core Hospital for the Treatment of Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[The Role of Coordinators for Intractable Diseases in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

7.5K

[Ascorbic Acid and Charcot-Marie-Tooth Disease].

Yu-ichi Noto1

  • 1Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 10, 2015
PubMed
Summary
This summary is machine-generated.

Ascorbic acid showed promise for Charcot-Marie-Tooth disease type 1A (CMT1A) in mice, but human trials failed to show significant benefits. Future clinical trials for CMT1A can learn from these disappointing outcomes.

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.3K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

2.3K

Related Experiment Videos

Last Updated: Apr 1, 2026

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

7.5K
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.3K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

2.3K

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Context:

  • Charcot-Marie-Tooth disease type 1A (CMT1A) is a progressive, inherited peripheral neuropathy with no current drug treatments.
  • Previous research indicated ascorbic acid could reduce PMP22 mRNA, improve motor function, and increase myelinated axons in a CMT1A mouse model.

Purpose:

  • To evaluate the clinical effectiveness of ascorbic acid as a potential treatment for Charcot-Marie-Tooth disease type 1A.
  • To assess the therapeutic potential of targeting PMP22 mRNA levels in human CMT1A patients.

Summary:

  • Five global clinical trials investigated ascorbic acid for CMT1A based on promising preclinical data.
  • None of the trials demonstrated statistically significant improvements in patient outcomes or disease markers.
  • Despite the negative results, the trials yielded valuable data for future CMT1A research.

Impact:

  • The clinical trials highlight the challenges in translating preclinical findings to human efficacy for CMT1A.
  • These studies provide crucial insights into trial design and patient stratification for future CMT1A therapeutic development.
  • Further research is needed to identify effective treatments for this debilitating neurological disorder.